Oblita Therapeutics, located in Belgium, is a global health research & development company dedicated to the development of new or improved affordable medicines for the treatment of neglected (tropical) diseases in the world. Her mission is to close current therapeutic gaps and improve the quality of life of those suffering from neglected diseases.
Oblita started its activities as a new start-up in March 2016, taking over the R&D department of Dafra Pharma International, including all IP, data, know-how and contracts.
Oblita will be responsible for the sourcing of the API (including stability studies). She will also coordinate the dissemination and communication activities within the consortium. Important valorisation exercise is the preparation of the regulatory files, because without registration at a stringent authority there can never be a market introduction nor reach out to the patients. Valorisation of the project will only happen when co-investors step into Oblita Therapeutics. Therefor the search for investors will be part of the project.
